It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications; Inno ...

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

CRISPR is a powerful gene-editing tool that holds enormous potential for treating genetic diseases by allowing scientists to ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating on January 14.Stay Ahead of the ...

Luckily, most streaming services these days offer a sneak peek via free trials into their cache of goodies. So whatever you’re looking to watch in 2025, these nine free trials are a great way to ...

CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced initiation of the GALLOP Phase 1 clinical trial evaluating CB-010 in patients with lupus nephritis ...

The company ended 2024 with $862m in cash, which it says will fund operations through the first half of 2027, including its three ongoing Phase III clinical trials. Intellia is prioritising NTLA-2002, ...

As pharmaceutical and biopharma companies conduct clinical trials in more sites across more countries, clinical services organizations are essential to drug development value chains. “Increasing ...